Overview

Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A Phase 2 trial of avelumab plus gemcitabine in advanced leiomyosarcoma as a second line treatment
Phase:
Phase 2
Details
Lead Sponsor:
Gachon University Gil Medical Center
Collaborators:
Chong Kun Dang Pharmaceutical Corp.
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Antibodies, Monoclonal
Avelumab
Gemcitabine